[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"local-injection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:local-injection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100633191","local-injection-of-botulinium-toxin-a-in-children-with-dysfunctional-voiding-or-refractory-nocturnal-eneuresis-100633191",false,"NCT07523477","Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Inclusion Criteria:\n\n* Children \\\u003C 18 years.\n* Both sexes.\n* Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.\n\nExclusion Criteria:\n\n* Bleeding disorders.\n* Neuromusclar disorder(e.g.,Myasthenia gravis).\n* Patients who are not fit for anaesthesia.\n* Active urinary tract infection (UTI).","ALL","18 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with :\n\nA-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.",[26,27,28,29,30],"Local Injection","Botulinium Toxin-A","Children","Dysfunctional Voiding","Refractory Nocturnal Eneuresis","RECRUITING","2026-04-05",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":35},"2025-06-01",{"date":39,"type":20},"2026-12-01",{"name":41,"class":42},"Tanta University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100626213","the-efficacy-and-safety-of-liposomal-bupivacaine-in-relieving-postoperative-pain-after-video-assisted-thoracoscopic-surgery-100626213","NCT07432711","The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;\n2. Ages 18 to 64 years old；\n3. American Society of Anesthesiologists (ASA) physical status of I-III；\n4. Glasgow Coma Scale (GCS) score of 15；\n5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause.\n2. Patients with heart conduction block (sinus block or atrioventricular block).\n3. Patients with unstable coronary artery disease.\n4. Patients with gastric ulcer or gastric bleeding.\n5. Patients with diabetes and are being treated with insulin.\n6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n7. Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n8. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n11. Pregnancy or breastfeeding.\n12. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n14. Patients with a history of allergy to local anaesthetics or one of the study drugs.","64 Years",{"count":53,"type":20},100,[23],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.",[57,58,59,26],"Video-assisted Thoracoscopic Surgery (VATS)","Pain Management","Liposomal Bupivacaine","2026-03-05",{"date":62,"type":35},"2026-03-06",{"date":64,"type":35},"2026-03-02",{"date":66,"type":20},"2027-06-30",{"name":68,"class":42},"Beijing Tiantan Hospital"]